Adherence to Exclusive Enteral Nutrition in Patients With Crohn's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04933214|
Recruitment Status : Unknown
Verified May 2021 by Second Affiliated Hospital, School of Medicine, Zhejiang University.
Recruitment status was: Recruiting
First Posted : June 21, 2021
Last Update Posted : June 21, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||131 participants|
|Official Title:||Adherence to Exclusive Enteral Nutrition in Patients With Crohn's Disease|
|Actual Study Start Date :||May 12, 2021|
|Estimated Primary Completion Date :||December 12, 2021|
|Estimated Study Completion Date :||December 12, 2021|
- Adherence [ Time Frame: December 2020 to May 2021 ]The adherence of patients was evaluated by the ratio of daily actual intake of energy to daily target energy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||14 Years and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- The main inclusion criteria were as follows: had diagnosed CD more than 3 months; had EEN in the past 6 months; were at least 18 years old; agreed to participate in this study.
- The exclusion criteria were received treatment from mental health professionals due to any mental or cognitive impairment; suffered from other serious diseases, such as heart, brain, lung, liver and kidney dysfunction; severe infection, anemia, cachexia or other serious complications were found.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04933214
|Contact: Zexin Chenfirstname.lastname@example.org|
|2ndAffiliated Hospital, School of Medicine, Zhejiang University, China||Recruiting|
|Study Director:||Yan Chen||2ndAffiliated Hospital, School of Medicine, Zhejiang University, China|
|Responsible Party:||Second Affiliated Hospital, School of Medicine, Zhejiang University|
|Other Study ID Numbers:||
|First Posted:||June 21, 2021 Key Record Dates|
|Last Update Posted:||June 21, 2021|
|Last Verified:||May 2021|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Crohn's disease, Exclusive Enteral Nutrition, Adherence
Inflammatory Bowel Diseases
Digestive System Diseases